CD19: a biomarker for B cell development, lymphoma diagnosis and therapy. - Wikidata - wikimedia - TriplyDB

CD19: a biomarker for B cell development, lymphoma diagnosis and therapy.

CD19: a biomarker for B cell development, lymphoma diagnosis and therapy.

http://www.wikidata.org/entity/Q38064963

about

Novel agents for chronic lymphocytic leukemia The role of blinatumomab in patients with relapsed/refractory acute lymphoblastic leukemia Anti-CD19 Monoclonal Antibodies: a New Approach to Lymphoma Therapy Blinatumomab: a bispecific T cell engager (BiTE) antibody against CD19/CD3 for refractory acute lymphoid leukemia Novel agents and biomarkers for acute lymphoid leukemia Blinatumomab: enlisting serial killer T-cells in the war against hematologic malignancies Antigen-based immunotherapy for the treatment of acute lymphoblastic leukemia: the emerging role of blinatumomab Development of Novel Immunotherapies for Multiple Myeloma Second-generation inhibitors of Bruton tyrosine kinase Mitochondrial structure alteration in human prostate cancer cells upon initial interaction with a chemopreventive agent phenethyl isothiocyanate Synergistic effect of paclitaxel and epigenetic agent phenethyl isothiocyanate on growth inhibition, cell cycle arrest and apoptosis in breast cancer cells STAT inhibitors for cancer therapy.Clinical Pharmacology and Translational Aspects of Bispecific Antibodies Construction and expression of a novel anti-CD14 human-mouse chimeric antibody Hm2F9 Comparison of mesenchymal stem cell markers in multiple human adult stem cells Critical role of SHP2 (PTPN11) signaling in germinal center-derived lymphoma.Simultaneous downregulation of KLF5 and Fli1 is a key feature underlying systemic sclerosis.Cloning and Expression of CD19, a Human B-Cell Marker in NIH-3T3 Cell Line.Nephrotoxicity of recent anti-cancer agents.Inhibition of Lyn is a promising treatment for mantle cell lymphoma with bortezomib resistance.Single nucleotide polymorphisms of CD20 gene and their relationship with clinical efficacy of R-CHOP in patients with diffuse large B cell lymphoma.Target Therapy in Hematological Malignances: New Monoclonal Antibodies.Differential gene expression profiles of PPP2R5C-siRNA-treated malignant T cells.Phosphatidylinositol 3-kinase (PI3K) inhibitors as cancer therapeutics.Ibrutinib for B cell malignancies.Elevated Th22 cells correlated with Th17 cells in peripheral blood of patients with acute myeloid leukemia.Generation of Monoclonal Antibodies against Immunoglobulin Proteins of the Domestic Ferret (Mustela putorius furo).Ibrutinib and novel BTK inhibitors in clinical development.CAR-modified anti-CD19 T cells for the treatment of B-cell malignancies: rules of the road.Selective inhibitors of nuclear export (SINE)--a novel class of anti-cancer agents.CD19: A multifunctional immunological target molecule and its implications for Blineage acute lymphoblastic leukemia.Changes in clinical laboratory parameters and pharmacodynamic markers in response to blinatumomab treatment of patients with relapsed/refractory ALL Blinatumomab: a CD19/CD3 bispecific T cell engager (BiTE) with unique anti-tumor efficacy.Engineering of synthetic gene circuits for (re-)balancing physiological processes in chronic diseases.CD19 negative precursor B acute lymphoblastic leukemia (B-ALL)-Immunophenotypic challenges in diagnosis and monitoring: A study of three cases.Bruton tyrosine kinase inhibitor ONO/GS-4059: from bench to bedside.The Immune System in Cancer Pathogenesis: Potential Therapeutic Approaches.Translation and Clinical Development of Bispecific T-cell Engaging Antibodies for Cancer Treatment.Diagnosis and treatment of CD20 negative B cell lymphomas.Identification of an Atypical Enzootic Bovine Leukosis in Japan by Using a Novel Classification of Bovine Leukemia Based on Immunophenotypic Analysis.

P2860

Q21198858-41552BF2-24E8-4BAB-AF1D-1B03EF4C8F2A Q26744280-8DD132CD-845A-46DB-84E0-4353EE658B0F Q26775363-61C09F37-7DDE-419A-B4BA-5F8DE2DF51FA Q26785828-0A1BF0BC-993B-492F-BC66-C4EA5F48985F Q26829775-A45F8A25-0E4F-41C6-88D2-0A4E584099C8 Q26865838-B399EB15-C1C2-4771-9DED-FFF471BF609A Q27013710-7C5CBECD-2477-4B4B-8638-B6D89F9DE823 Q28066890-0C711255-4396-423B-8847-8B56CBC118DF Q28076118-1A0723B0-C60C-424E-942F-700847860656 Q28384383-8FEB8B90-CF83-471C-979E-918738FE7873 Q28397373-E318A728-F448-4555-8C0E-BB148E17396B Q33644206-975D88BB-C7FA-4751-8E53-ADDA7D12334C Q33648086-979323D6-9BA6-4D02-8500-FF92C371E1BE Q34088284-5DDAFF1F-021C-496E-8A1B-0C35D3CF85AB Q34599681-C92193CE-A957-4163-BA21-F7E6FB4317EA Q34649044-8BFEB660-50D1-48F6-9CB3-4831F23724A9 Q34721223-F64AB532-C083-459E-80DC-09A0ED28E980 Q35307091-AE788307-7ED0-4274-BDD4-69E8B1ED86F8 Q35310741-A0754310-5B7E-40BA-BA94-E09392D0AAE0 Q36546004-3BB15739-EDB4-43D1-88BF-B7D205203DD3 Q36940760-D3C17446-0D99-4BA1-8849-E2AB8C88CAB0 Q36979140-9CD7BE51-924C-4FE3-9A30-4402AE56FC42 Q37202568-C3072D32-3B31-4B8B-966A-AD2A202490E0 Q37350230-2F67625B-3C61-4D9D-91D0-069923D2DADC Q37555418-0E6C0C70-F0C1-4642-AFF7-B8E7C8CB559C Q37645126-D1D6461C-575F-4752-9408-D0032765D6AE Q37670852-0124810F-88C2-48E7-B789-FD14E26DD87E Q38130010-E2AD5ED8-A021-44B8-B160-543EF4CC6971 Q38164792-A20B4E77-469A-4993-8983-544CC9478272 Q38260357-06B7CB51-2BBC-4A01-979B-CF3ECB4599DB Q38371387-8D86BAF6-F5B3-48D6-9F55-57248728058F Q38376489-8996749B-CCE0-4A2F-9529-0557D3536E1B Q38799449-AB19AD92-27F6-4E6D-8AAA-867F31BF6D7A Q38876131-A8204CF3-B8D1-495F-9A18-A1FD0E7C8B6F Q38889598-BEFE782A-54F1-4C94-B069-5AB46262915B Q38989496-095E9F73-632C-4915-9738-B82EE081D50E Q39100049-8BEF09B6-2F84-4940-8E5C-8E16FE105B33 Q39128240-58E5941F-3255-48B9-9A81-D3C9643E4E8D Q39132786-37E12794-248B-40B0-8ED2-8FB678B4FC4C Q40142063-5E962BD7-2FDF-4295-B493-75A207E8B1F9

P2860

CD19: a biomarker for B cell development, lymphoma diagnosis and therapy.

http://www.wikidata.org/entity/Q38064963

description

2012 nî lūn-bûn

@nan

2012年の論文

@ja

2012年学术文章

@wuu

2012年学术文章

@zh-cn

2012年学术文章

@zh-hans

2012年学术文章

@zh-my

2012年学术文章

@zh-sg

2012年學術文章

@yue

2012年學術文章

@zh

2012年學術文章

@zh-hant

name

CD19: a biomarker for B cell development, lymphoma diagnosis and therapy.

@en

type

label

CD19: a biomarker for B cell development, lymphoma diagnosis and therapy.

@en

prefLabel

CD19: a biomarker for B cell development, lymphoma diagnosis and therapy.

@en

P1433

Q38064963-5FE69D09-7FC3-4A05-BEA0-CFEAFE495A7D

P1476

Q38064963-7C81BC6B-AB1D-4C26-936B-35D0B766C7C0

P2093

Q38064963-08F0669B-875E-4884-BF46-9D1FD4E35769

Q38064963-40967BA9-8759-46BC-9D92-195C18FEA626

Q38064963-AB616398-CB04-4CCC-A952-3BB6C985DAE8

P2860

Q38064963-0189B143-9267-4D0E-BDCA-72E581D3B678

Q38064963-062E2A09-0475-41C0-A684-DF248383F14C

Q38064963-14253740-5113-4398-BD56-63121265F6FB

Q38064963-14616B2C-E4D9-439F-BFEA-F981FEC3A68E

Q38064963-19A08682-84C5-4AEC-8FAC-F696A86C2931

Q38064963-21B64BA4-C03D-44FE-81AD-1E5469563E82

Q38064963-21D91AC7-38C2-4500-AB09-1D4BF668AC51

Q38064963-3A2D32F8-FB53-4896-AA6D-F87A239C5884

Q38064963-43193AE0-FE33-4D5D-9FAB-E5BD85C1B980

Q38064963-51B5CF79-8426-4BF6-8142-777091071138

P2888

Q38064963-2A9C7F08-FBBC-43BC-935A-235F133B1A92

P304

Q38064963-398277CE-09D7-4F3B-B5EF-CF5CC146A10B

P31

Q38064963-5AD94C74-0CCD-450D-BC50-5D32C7BF5042

Q38064963-f2fff4f3-66d5-4436-8504-196b46a746d0

P356

Q38064963-8CEE810C-EE28-4EAC-8660-38EE97F16892

P433

Q38064963-210CBF98-C03D-46D5-9FD1-6A030A632070

P478

Q38064963-80518F17-B0C5-4370-98BC-0EDD346EEC98

P577

Q38064963-661480F6-8752-49A2-8B6B-1E1BBA2326AD

P5875

Q38064963-6B064C86-AFF7-4AD0-B9C5-2CB273A47324

P6179

Q38064963-FEF4C147-AEE6-467A-BE81-B7BB3A650465

P698

Q38064963-9EBA59C1-74B7-4BA6-9B47-6E01F8A4D0AB

P921

Q38064963-70C89FED-AA11-401B-B284-CB57C4BDDA60

P932

Q38064963-87E58294-AED8-4A13-BB9C-623FC8C8CA64

P356

P1433

Experimental Hematology & Oncology

P1476

CD19: a biomarker for B cell development, lymphoma diagnosis and therapy.

@en

P2093

Delong Liu

http://www.w3.org/2001/XMLSchema#string

Guoqing Wei

http://www.w3.org/2001/XMLSchema#string

Kemeng Wang

http://www.w3.org/2001/XMLSchema#string

P2860

AceView: a comprehensive cDNA-supported gene and transcripts annotation

Isolation of cDNAs encoding the CD19 antigen of human and mouse B lymphocytes. A new member of the immunoglobulin superfamily

CD19: lowering the threshold for antigen receptor stimulation of B lymphocytes

Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia

T cells with chimeric antigen receptors have potent antitumor effects and can establish memory in patients with advanced leukemia

Structure of the genes encoding the CD19 antigen of human and mouse B lymphocytes

The CD19/CD21 signal transducing complex of human B lymphocytes includes the target of antiproliferative antibody-1 and Leu-13 molecules

CD19 expression and growth inhibition of tumours in human multiple myeloma

An antibody-deficiency syndrome due to mutations in the CD19 gene

CD19 is a major B cell receptor-independent activator of MYC-driven B-lymphomagenesis

P2888

P304

36

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1186/2162-3619-1-36

http://www.w3.org/2001/XMLSchema#string

P433

1

http://www.w3.org/2001/XMLSchema#string

P478

1

http://www.w3.org/2001/XMLSchema#string

P577

2012-11-29T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

233847835

http://www.w3.org/2001/XMLSchema#string

P6179

1030655151

http://www.w3.org/2001/XMLSchema#string

P698

23210908

http://www.w3.org/2001/XMLSchema#string

P921

P932

3520838

http://www.w3.org/2001/XMLSchema#string